US · ADCT
ADC Therapeutics S.A.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Epalinges 1066
- Website
- adctherapeutics.com
Price · as of 2024-12-31
$3.83
Market cap 507.9M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.15 | +504.44% |
| Intrinsic Value(DCF) | $0.74 | -80.68% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $61.90 | |||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $25.28 | $34.37 | |||
| 2021 | $14.02 | $0.00 | $0.00 | ||
| 2022 | $2.74 | $71.86 | $29,695.50 | $0.00 | $0.00 |
| 2023 | $4.50 | $27.56 | $0.00 | $0.00 | $163.83 |
| 2024 | $1.84 | $23.15 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates ADC Therapeutics S.A.'s (ADCT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.15
- Current price
- $3.83
- AI upside
- +504.44%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.74
-80.68% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ADCT | ADC Therapeutics S.A. | $3.83 | 507.9M | +504% | -81% | — | — | -1.13 | -0.88 | 2.52 | -0.50 | — | -0.88 | 91.60% | -184.44% | -222.83% | 89.97% | 41.28% | -46.65% | -0.61 | -2.60 | 3.82 | 3.37 | 1.25 | -4490.00% | 184.00% | 230.00% | -69.75% | -1.54 | 39.40% | 0.00% | 0.00% | 0.00% | -0.39 | -0.41 | 0.72 | -6.56 |
| ALMS | Alumis Inc. Common Stock | $29.69 | 3.1B | — | — | — | — | -0.47 | 0.53 | — | 0.40 | -0.19 | 0.53 | 0.00% | — | — | 743.42% | 170.37% | -136.66% | 0.12 | — | 6.01 | 5.70 | 0.47 | 24716.00% | — | 9097.00% | -185.69% | -5.01 | 145.47% | 0.00% | 0.00% | 90.66% | 0.40 | 0.46 | — | -3.69 |
| AUTL | Autolus Therapeutics plc | $1.71 | 455.11M | +3,826% | -33% | — | — | -2.32 | 1.20 | 50.68 | 0.10 | — | 1.24 | -1293.48% | -2385.63% | -2180.45% | -81.91% | 263.57% | -38.11% | 0.12 | -25.98 | 10.88 | 10.47 | 0.75 | -2750.00% | 49600.00% | 5398.00% | -47.01% | -3.40 | 263.21% | 0.00% | 0.00% | 0.00% | 0.09 | 0.09 | -2.23 | -1.19 |
| BCYC | Bicycle Therapeutics plc | $5.73 | 397.02M | +373% | +110% | — | — | -3.52 | 0.75 | 16.88 | 1.67 | — | 0.75 | -390.34% | -594.96% | -479.18% | -29.04% | 217.72% | -21.78% | 0.01 | -121.31 | 13.81 | 13.61 | 5.28 | -4291.00% | 3076.00% | 16112.00% | -27.87% | -2.45 | 177.02% | 0.00% | 0.00% | 65.25% | 1.31 | 1.65 | -7.78 | 1.58 |
| FDMT | 4D Molecular Therapeutics… | $9.66 | 492.74M | +142% | -52% | — | +2,596% | -1.36 | 0.43 | 5933.81 | 1.00 | -8.80 | 0.43 | 100.00% | -507678.38% | -434778.38% | -39.31% | -259.80% | -35.74% | 0.05 | — | 14.92 | 14.58 | 0.69 | 1550.00% | -9982.00% | 7613.00% | -63.02% | -4.62 | -191.38% | 0.00% | 0.00% | 0.00% | 0.96 | 1.31 | -4884.32 | 0.97 |
| LXRX | Lexicon Pharmaceuticals, … | $1.47 | 581.34M | +24,271% | +1,124% | — | — | -0.62 | 0.86 | 4.02 | 0.03 | — | 1.23 | 98.02% | -634.20% | -644.78% | -167.66% | -865.73% | -75.93% | 0.74 | -12.65 | 5.44 | 5.34 | -0.23 | -2125.00% | 248148.00% | 1074.00% | -144.07% | -3.95 | -789.72% | 0.00% | 0.00% | 34.92% | 0.02 | 0.03 | -0.15 | -10.01 |
| NMRA | Neumora Therapeutics, Inc… | $3.49 | 583.14M | — | — | — | — | -0.97 | 0.83 | — | 0.26 | -36.29 | 0.83 | 0.00% | — | — | -64.48% | -31666.35% | -59.96% | 0.01 | — | 10.51 | 10.29 | 0.53 | 268.00% | — | 1196.00% | -77.03% | -6.12 | -21987.50% | 0.00% | 0.00% | 0.00% | 0.26 | 0.37 | — | -1.09 |
| OMER | Omeros Corporation | $12.05 | 854.35M | — | — | — | — | -2.84 | -2.44 | — | -3.58 | -6.51 | -2.44 | 0.00% | — | — | 151.08% | -341.82% | -47.86% | -1.13 | -6.86 | 1.69 | 1.60 | -1.30 | 4362.00% | — | -30050.00% | -33.43% | -1.87 | -300.85% | 0.00% | 0.00% | 36.52% | -3.32 | -3.78 | — | -5.80 |
| QSI | Quantum-Si incorporated | $0.96 | 187.03M | +4,402% | -8% | — | — | -1.83 | 0.86 | 60.41 | 0.11 | -41.45 | 0.86 | 52.32% | -3550.56% | -3303.04% | -41.48% | -452.86% | -36.99% | 0.06 | — | 11.99 | 11.60 | 0.35 | 441.00% | 18262.00% | -698.00% | -50.01% | -4.83 | -385.30% | 0.00% | 0.00% | 0.00% | 0.11 | 0.13 | -3.90 | -0.42 |
| RAPT | RAPT Therapeutics, Inc. | $57.98 | 958.84M | — | — | — | — | -0.35 | 0.24 | — | 1.34 | -7.75 | 0.24 | 0.00% | — | — | -77.09% | 654.65% | -62.79% | 0.02 | — | 4.87 | 4.78 | 1.22 | 458.00% | — | -1503.00% | -181.11% | -1.72 | 401.25% | 0.00% | 0.00% | 270.67% | 1.33 | 2.16 | — | -3.97 |
About ADC Therapeutics S.A.
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
- CEO
- Ameet Mallik
- Employees
- 263
- Beta
- 1.95
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.74 ÷ $3.83) − 1 = -80.68% (DCF, example).